Home » Clinical Trials » Leukemia » NCT06393335
NCT06393335

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Study Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies

Want to learn more about this trial?

Request More Info

Interventions

Metabolically Armed CD19 CAR-T cellsDRUG
Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.

Study Locations

FacilityCityStateCountry
Children's Hospital of Zhejiang University School of MedicineHangzhouZhejiangChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026